Abstract

Bile acid synthesis plays a key role in regulating whole body cholesterol homeostasis. Transcriptional factor EB (TFEB) is a nutrient and stress-sensing transcriptional factor that promotes lysosomal biogenesis. Here we report a role of TFEB in regulating hepatic bile acid synthesis. We show that TFEB induces cholesterol 7α-hydroxylase (CYP7A1) in human hepatocytes and mouse livers and prevents hepatic cholesterol accumulation and hypercholesterolemia in Western diet-fed mice. Furthermore, we find that cholesterol-induced lysosomal stress feed-forward activates TFEB via promoting TFEB nuclear translocation, while bile acid-induced fibroblast growth factor 19 (FGF19), acting via mTOR/ERK signaling and TFEB phosphorylation, feedback inhibits TFEB nuclear translocation in hepatocytes. Consistently, blocking intestinal bile acid uptake by an apical sodium-bile acid transporter (ASBT) inhibitor decreases ileal FGF15, enhances hepatic TFEB nuclear localization and improves cholesterol homeostasis in Western diet-fed mice. This study has identified a TFEB-mediated gut-liver signaling axis that regulates hepatic cholesterol and bile acid homeostasis.

TFEB is a transcriptional regulator of lysosomal biogenesis, activated upon starvation or lysosomal stress. Here the authors report that TFEB regulates hepatic bile acid synthesis downstream of FGF19 signaling.

Details

Title
An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis
Author
Wang, Yifeng 1 ; Gunewardena Sumedha 2 ; Li, Feng 3 ; Matye, David J 4 ; Chen, Cheng 1 ; Chao Xiaojuan 1 ; Jung Taeyoon 1   VIAFID ORCID Logo  ; Zhang, Yuxia 1 ; Czerwiński Maciej 5 ; Hong-Min, Ni 1 ; Wen-Xing, Ding 1   VIAFID ORCID Logo  ; Li, Tiangang 6   VIAFID ORCID Logo 

 University of Kansas Medical Center, Department of Pharmacology, Toxicology and Therapeutics, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375) 
 University of Kansas Medical Center, Department of Molecular and Integrative Physiology, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375) 
 Baylor College of Medicine, Department of Molecular and Cellular Biology, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X) 
 University of Kansas Medical Center, Department of Pharmacology, Toxicology and Therapeutics, Kansas City, USA (GRID:grid.412016.0) (ISNI:0000 0001 2177 6375); University of Oklahoma Health Sciences Center, Harold Hamm Diabetes Center, Department of Physiology, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618) 
 Sekisui XenoTech LLC, Kansas City, USA (GRID:grid.422828.6) (ISNI:0000 0004 1798 670X) 
 University of Oklahoma Health Sciences Center, Harold Hamm Diabetes Center, Department of Physiology, Oklahoma City, USA (GRID:grid.266902.9) (ISNI:0000 0001 2179 3618) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2424567501
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.